Clinical trials: Progressive Gliosarcoma
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
This phase II trial is studying how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with recurrent or progressive glioblastoma.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT01122901
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, pharmacological study
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of erlotinib in treating patients with…
- Trial name
- NCT00227032
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Brain and Central Nervous System Tumors
VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00516282
- Testing
- CLORETAZINE, temozolomide
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Northwestern University
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
This phase I trial is studying the side effects and best dose of sorafenib in treating patients with recurrent or progressive malignant glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00093613
- Testing
- sorafenib tosylate, pharmacological study
- Where
- 10 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005855
- Testing
- carmustine, efaproxiral
- Where
- 9 sites in United States
- Volunteers
- 48 people
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
This phase II trial studies how well dovitinib works in treating patients with recurrent or progressive glioblastoma. Dovitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT01753713
- Testing
- dovitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Manmeet Ahluwalia, MD
Teratoid Tumor, Atypical, Choroid Plexus Neoplasms
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
This phase I trial studies the side effects and best dose of azurin-derived cell-penetrating peptide p28 (p28) in treating patients with recurrent or progressive central nervous system tumors.
- Conditions
- Teratoid Tumor, Atypical, Choroid Plexus Neoplasms, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT01975116
- Testing
- azurin-derived cell-penetrating peptide p28
- Where
- 11 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain and Central Nervous System Tumors
Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00003574
- Testing
- surgical procedure, brachytherapy, intraoperative radiation therapy
- Where
- 9 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
This phase II trial is studying how well giving vorinostat together with bortezomib works in treating patients with progressive, recurrent glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00641706
- Testing
- vorinostat, therapeutic conventional surgery, bortezomib
- Where
- 214 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
RATIONALE: Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00047281
- Testing
- celecoxib, cyclophosphamide, etoposide
- Where
- 3 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Brain and Central Nervous System Tumors
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or…
- Trial name
- NCT00054496
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- The Cleveland Clinic
Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
This phase II trial compares the effect of GI-102 alone and in combination with pembrolizumab given before surgery in treating patients with IDH wildtype glioblastoma and IDH mutated grade 4 astrocytoma that has come back after a…
- Conditions
- Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4, Progressive Glioblastoma, Progressive Gliosarcoma
- Trial name
- NCT07301268
- Testing
- Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
This phase I trial is studying the side effects and best dose of cediranib maleate when given together with cilengitide in treating patients with progressive or recurrent glioblastoma.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00979862
- Testing
- Cediranib Maleate, Cilengitide, Laboratory Biomarker Analysis
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00795665
- Testing
- bevacizumab, carmustine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, Davis
Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment.
- Conditions
- Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma
- Trial name
- NCT02255461
- Testing
- palbociclib isethionate, pharmacological study, laboratory biomarker analysis
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pediatric Brain Tumor Consortium
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
This phase I/II trial is studying the side effects and the best dose of RO4929097 to see how well it works when given together with bevacizumab compared to bevacizumab alone in treating patients with progressive or recurrent…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT01189240
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab, laboratory biomarker analysis
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00892177
- Testing
- bevacizumab, dasatinib
- Where
- 305 sites in United States
- Volunteers
- 144 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Glioblastoma, Gliosarcoma
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
This phase II clinical trial studies how well ERC1671 plus Granulocyte-macrophage colony-stimulating factor (GM-CSF) plus Cyclophosphamide with Bevacizumab works compared to Placebo Injection plus Placebo Pill with Bevacizumab in…
- Trial name
- NCT01903330
- Testing
- ERC1671, GM-CSF, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 84 people
- Sponsor
- Epitopoietic Research Corporation
Brain and Central Nervous System Tumors
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
RATIONALE: Thalidomide may stop the growth of malignant glioma by stopping blood flow to the tumor. Drugs used in chemotherapy, such as procarbazine, work in different ways to stop tumor cells from dividing so they stop growing…
- Trial name
- NCT00079092
- Testing
- procarbazine hydrochloride, thalidomide
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Adult Brain Tumor, Adult Giant Cell Glioblastoma
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
This phase I/II trial is studying the side effects and best dose of tandutinib and to see how well it works in treating patients with recurrent or progressive glioblastoma.Tandutinib may stop the growth of tumor cells by blocking…
- Conditions
- Adult Brain Tumor, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00379080
- Testing
- conventional surgery, tandutinib, pharmacological study
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)